Cancer vaccines inducing antibody production: More pros than cons

Expert Review of Vaccines

Volumn 10, Issue 9, 2011, Pages 1281-1289

  Jensen Jarolim, Erika ^a,b   Singer, Josef ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

Author keywords

active passive immunotherapy; antibody therapy; cancer; DNA; IgE; mimotope; passive; Treg; tumor vaccine

Indexed keywords

BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; PROVENGE; RITUXIMAB; TRASTUZUMAB;

ACTIVE IMMUNIZATION; ANTIBODY PRODUCTION; B LYMPHOCYTE; DRUG COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW;

ANTIBODIES; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY, ACTIVE; INDIVIDUALIZED MEDICINE; MODELS, MOLECULAR; NEOPLASMS;

EID: 80052981497     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.105     Document Type: Review

References (107)

1. Plymoth A, Viviani S, Hainaut P. Control of hepatocellular carcinoma through hepatitis B vaccination in areas of high endemicity: perspectives for global liver cancer prevention. Cancer Lett. 286(1), 15-21 (2009).
2. Schiller JT, Lowy DR. Prospects for cervical cancer prevention by human papillomavirus vaccination. Cancer Res. 66(21), 10229-10232 (2006). (Pubitemid 44799735)
3. Suzich JA, Ghim SJ, Palmer-Hill FJ et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl Acad. Sci. USA 92(25), 11553-11557 (1995). (Pubitemid 26014152)
4. Bergman PJ, Camps-Palau MA, Mcknight JA et al. Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the animal medical center. Vaccine 24(21), 4582-4585 (2006). (Pubitemid 44218845)
5. Bilusic M, Madan RA. Therapeutic cancer vaccines: the latest advancement in targeted therapy. Am. J. Ther. DOI: 10.1097/ MJT.0b013e3182068cdb (2011) (Epub ahead of print).
6. Monzavi-Karbassi B, Artaud C, Jousheghany F et al. Reduction of spontaneous metastases through induction of carbohydrate cross-reactive apoptotic antibodies. J. Immunol. 174(11), 7057-7065 (2005). (Pubitemid 40705671)
7. The future of monoclonal antibodies therapeutics: innovation in antibody engineering, key growth strategies and forecasts to 2011. Business Insights (2006).
8. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 9(4), 325-338 (2010).
9. Siena S, Glynne-Jones R, Adenis A et al. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 116(7), 1827-1837 (2010).
10. Schwartzberg LS, Stepanski EJ, Fortner BV, Houts AC. Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences. Support Care Cancer 16(4), 393-398 (2008). (Pubitemid 351667051)
11. Chung CH, Mirakhur B, Chan E et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1,3-galactose. N. Engl. J. Med. 358(11), 1109-1117 (2008). (Pubitemid 351398485)
12. Sorensen RU, Leiva LE, Giangrosso PA et al. Response to a heptavalent conjugate Streptococcus pneumoniae vaccine in children with recurrent infections who are unresponsive to the polysaccharide vaccine. Pediatr. Infect. Dis. J. 17(8), 685-691 (1998). (Pubitemid 28388156)
13. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J. Rheumatol. 34(2), 272-279 (2007).
14. Lai CC, Lee LN, Yu CJ et al. Antibody responses to pneumococcal polysaccharide vaccine in Taiwanese patients with chronic obstructive pulmonary disease. J. Formos. Med. Assoc. 106(3), 196-203 (2007).
15. Schauer U, Stemberg F, Rieger Ch et al. Levels of antibodies specific to tetanus toxoid, Haemophilus influenzae type b, and pneumococcal capsular polysaccharide in healthy children and adults. Clin. Diagn. Lab Immunol. 10(2), 202-207 (2003). (Pubitemid 36314441)
16. Gentili G, Damelio R, Wirz M et al. Prevalence of hyperimmunization against tetanus in Italians born after the introduction of mandatory vaccination of children with tetanus toxoid in 1968. Infection 21(2), 80-82 (1993). (Pubitemid 23112592)
17. Amos SM, Duong CP, Westwood JA et al. Autoimmunity associated with immunotherapy of cancer. Blood 118(3), 499-509 (2011).
18. Finn OO, Banchereau J. Cancer vaccines: the state of the art. Semin. Immunol. 22(3), 103-104 (2010).
19. Ryan SO, Turner MS, Gariepy J, Finn OJ. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res. 70(14), 5788-5796 (2010).
20. Farkas AM, Finn OJ. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin. Immunol. 22(3), 125-131 (2010).
21. Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol. 8(12), 970-976 (2008).
22. Correale P, Fioravanti A, Bertoldi I, Montagnani F, Miracco C, Francini G. Occurrence of autoimmunity in a longterm survivor with metastatic colon carcinoma treated with a new chemoimmunotherapy regimen. J. Chemotherapy 20(2), 278-281 (2008). (Pubitemid 351797071)
23. Towns K, Bedard PL, Verma S. Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr. Oncol. 15, S16-S29 (2008).
24. Mcbride WH, Chiang CS, Olson JL et al. Failla memorial lecture - a sense of danger from radiation. Radiat. Res. 162(1), 1-19 (2004). (Pubitemid 39044714)
25. Smyth PP, Shering SG, Kilbane MT et al. Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J. Clin. Endocrinol. Metab. 83(8), 2711-2716 (1998). (Pubitemid 28493765)
26. Kilbane M, Shering S, Symith D, Mcdermott E, Ohiggins N, Symith P. Thyroid peroxidase (TPO): an autoantigen common to the thyroid and breast. J. Endocrinol. 156, 323 (1998).
27. Bouwhuis MG, Ten Hagen TL, Suciu S, Eggermont AM. Autoimmunity and treatment outcome in melanoma. Curr. Opin. Oncol. 23(2), 170-176 (2011).
28. Pardoll DM. Inducing autoimmune disease to treat cancer. Proc. Natl Acad. Sci. USA 96(10), 5340-5342 (1999). (Pubitemid 29234615)
29. Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354(7), 709-718 (2006). (Pubitemid 43247141)
30. Lute KD, May KF Jr, Lu P et al. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 106(9), 3127-3133 (2005). (Pubitemid 41565910)
31. Greiner JW, Zeytin H, Anver MR, Schlom J. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res. 62(23), 6944-6951 (2002). (Pubitemid 35424085)
32. Wang LXJ, Westwood JA, Moeller M et al. Tumor ablation by gene-modified T cells in the absence of autoimmunity. Cancer Res. 70(23), 9591-9598 (2010).
33. Petkova SB, Akilesh S, Sproule TJ et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int. Immunol. 18(12), 1759-1769 (2006). (Pubitemid 44884038)
34. Shields RL, Namenuk AK, Hong K et al. High resolution mapping of the binding site on human IgG1 for Fc g RI, Fc g RII, Fc g RIII, and FcRn and design of IgG1 variants with improved binding to the Fc g R. J. Biol. Chem. 276(9), 6591-6604 (2001).
35. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357(1), 39-51 (2007). (Pubitemid 47026733)
36. Matter-Walstra KW, Dedes KJ, Schwenkglenks M, Brauchli P, Szucs TD, Pestalozzi BC. Trastuzumab beyond progression: a cost-utility analysis. Ann. Oncol. 21(11), 2161-2168 (2010).
37. Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J. Clin. Oncol. 25(12), 1539-1544 (2007). (Pubitemid 46733080)
38. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
39. Carballido E, Fishman M. Sipuleucel-T: prototype for development of anti-tumor vaccines. Curr. Oncol. Rep. 13(2), 112-119 (2011).
40. Romano E, Rossi M, Ratzinger G et al. Peptide-loaded langerhans cells, despite increased IL15 secretion and T cell activation in vitro, elicit anti-tumor T cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin. Cancer. Res. 17(7), 1984-1997 (2011).
41. Wang SJ. The state of art patent search with an example of human vaccines. Hum. Vaccine 7(2), 265-268 (2011).
42. Plotkin SA. Vaccines: past, present and future. Nat. Med. 11(4), S5-S11 (2005). (Pubitemid 40562297)
43. Mccullers JA. Evolution, benefits, and shortcomings of vaccine management. J. Manag. Care Pharm. 13(Suppl. 7B), S2-S6 (2007). (Pubitemid 47605360)
44. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975).
45. Reichert JM, Wenger JB. Development trends for new cancer therapeutics and vaccines. Drug Discov. Today 13(1-2), 30-37 (2008).
46. Dechant M, Beyer T, Schneider-Merck T et al. Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J. Immunol. 179(5), 2936-2943 (2007).
47. Otten MA, Rudolph E, Dechant M et al. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J. Immunol. 174(9), 5472-5480 (2005). (Pubitemid 40593187)
48. Fu SL, Pierre J, Smith-Norowitz TA et al. Immunoglobulin E antibodies from pancreatic cancer patients mediate antibodydependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin. Exp. Immunol. 153(3), 401-409 (2008).
49. Karagiannis P, Singer J, Hunt J et al. Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol. Immunother. 58(6), 915-930 (2009).
50. Jensen-Jarolim E, Achatz G, Turner MC et al. AllergoOncology: the role of IgEmediated allergy in cancer. Allergy 63(10), 1255-1266 (2008).
51. Brunner R, Jensen-Jarolim E, Pali-Scholl I. The ABC of clinical and experimental adjuvants - a brief overview. Immunol. Lett. 128(1), 29-35 (2010).
52. Riemer AB, Klinger M, Wagner S et al. Generation of peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J. Immunol. 173(1), 394-401 (2004). (Pubitemid 38797365)
53. Riemer AB, Untersmayr E, Knittelfelder R et al. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res. 67(7), 3406-3411 (2007). (Pubitemid 46724881)
54. Cecco S, Muraro E, Giacomin E et al. Cancer vaccines in Phase II/III clinical trials: state of the art and future perspectives. Curr. Cancer Drug Targets 11(1), 85-102 (2010).
55. Harwerth IM, Wels W, Schlegel J, Muller M, Hynes NE. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth. Br. J. Cancer 68(6), 1140-1145 (1993). (Pubitemid 23356666)
56. Hurwitz E, Stancovski I, Sela M, Yarden Y. Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-differentially correlate with cellular uptake. Proc. Natl Acad. Sci. USA 92(8), 3353-3357 (1995).
57. Yip YL, Smith G, Koch J, Dubel S, Ward RL. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J. Immunol. 166(8), 5271-5278 (2001). (Pubitemid 32280745)
58. Wiedermann U, Wiltschke C, Jasinska J et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neuspecific immune responses in patients with metastatic breast cancer: a Phase I study. Breast Cancer Res. Treat. 119(3), 673-683 (2010).
59. Zhao L, Liu Z, Fan D. Overview of mimotopes and related strategies in tumor vaccine development. Expert Rev. Vaccines 7(10), 1547-1555 (2008).
60. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced antiepidermal growth factor receptor antibodies. J. Natl Cancer Inst. 97(22), 1663-1670 (2005). (Pubitemid 41672232)
61. Hartmann C, Muller N, Blaukat A, Koch J, Benhar I, Wels WS. Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response. Oncogene 29(32), 4517-4527 (2010).
62. Yang L, Jiang H, Shi B et al. Identification and characterization of Ch806 mimotopes. Cancer Immunol. Immunother. 59(10), 1481-1487 (2010).
63. Witsch EJ, Mahlknecht G, Wakim J et al. Generation and characterization of peptide mimotopes specific for anti ErbB-2 monoclonal antibodies. Int. Immunol. 23(6), 391-403 (2011).
64. Jiang B, Liu W, Qu H et al. A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2. J. Biol. Chem. 280(6), 4656-4662 (2005). (Pubitemid 40288635)
65. Vaisman N, Nissim A, Klapper LN, Tirosh B, Yarden Y, Sela M. Specific inhibition of the reaction between a tumor-inhibitory antibody and the ErbB-2 receptor by a mimotope derived from a phage display library. Immunol. Lett. 75(1), 61-67 (2000). (Pubitemid 32332633)
66. Bramswig Kh, Knittelfelder R, Gruber S et al. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin. Cancer Res. 13(21), 6501-6508 (2007). (Pubitemid 350075041)
67. Meng FP, Ding J, Yu ZC et al. Oral attenuated Salmonella typhimurium vaccine against MG7-Ag mimotope of gastric cancer. World J. Gastroenterol. 11(12), 1833-1836 (2005). (Pubitemid 40520780)
68. Riemer AB, Hantusch B, Sponer B et al. High-molecular-weight melanomaassociated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol. Immunother. 54(7), 677-684 (2005). (Pubitemid 40884164)
69. Luo W, Ko E, Hsu JC, Wang X, Ferrone S. Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects. J. Immunol. 176(10), 6046-6054 (2006).
70. Wagner S, Krepler C, Allwardt D et al. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin. Cancer Res. 14(24), 8178-8183 (2008).
71. Perosa F, Favoino E, Vicenti C et al. Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20- associated epitopes. J. Immunol. 182(1), 416-423 (2009).
72. Riemer AB, Forster-Waldl E, Bramswig KH et al. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur. J. Immunol. 36(5), 1267-1274 (2006).
73. Fest S, Huebener N, Weixler S et al. Characterization of GD2 peptide mimotope DNA vaccines effective against spontaneous neuroblastoma metastases. Cancer Res. 66(21), 10567-10575 (2006). (Pubitemid 44799780)
74. Wierzbicki A, Gil M, Ciesielski M et al. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells. J. Immunol. 181(9), 6644-6653 (2008).
75. Gil M, Bieniasz M, Wierzbicki A, Bambach BJ, Rokita H, Kozbor D. Targeting a mimotope vaccine to activating Fc g receptors empowers dendritic cells to prime specific CD8+ T cell responses in tumor-bearing mice. J. Immunol. 183(10), 6808-6818 (2009).
76. Kozbor D. Cancer vaccine with mimotopes of tumor-associated carbohydrate antigens. Immunol. Res. 46(1-3), 23-31 (2010).
77. Hafner C, Wagner S, Jasinska J et al. Epitope-specific antibody response to Mel- CAM induced by mimotope immunization. J. Invest. Dermatol. 124(1), 125-131 (2005). (Pubitemid 40100960)
78. Shanmugam A, Suriano R, Chaudhuri D et al. Identification of PSA peptide mimotopes using phage display peptide library. Peptides 32(6), 1097-1102 (2011).
79. Ru B, Huang J, Dai P et al. MimoDB: a new repository for mimotope data derived from phage display technology. Molecules 15(11), 8279-8288 (2010).
80. Forster-Waldl E, Riemer AB, Dehof AK et al. Isolation and structural analysis of peptide mimotopes for the disialoganglioside GD2, a neuroblastoma tumor antigen. Mol. Immunol. 42(3), 319-325 (2005). (Pubitemid 39626764)
81. Chen Y, Wu K, Guo C et al. A novel DNA vaccine containing four mimicry epitopes for gastric cancer. Cancer Biol. Ther. 4(3), 308-312 (2005). (Pubitemid 41351291)
82. Lin T, Liang S, Meng F et al. Enhanced immunogenicity and antitumour effects with heterologous prime-boost regime using vaccines based on MG7-Ag mimotope of gastric cancer. Clin. Exp. Immunol. 144(2), 319-325 (2006).
83. Kowalczyk A, Wierzbicki A, Gil M et al. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery. Cancer Immunol. Immunother. 56(9), 1443-1458 (2007). (Pubitemid 47024709)
84. Bolesta E, Kowalczyk A, Wierzbicki A et al. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses. Cancer Res. 65(8), 3410-3418 (2005). (Pubitemid 40524627)
85. Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E. Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu - a new method of epitope definition. Mol. Immunol. 42(9), 1121-1124 (2005).
86. Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination - from allergy to cancer. Expert Opin. Biol. Ther. 9(4), 493-506 (2009).
87. Linnemann T, Tumenjargal S, Gellrich S et al. Mimotopes for tumor-specific T lymphocytes in human cancer determined with combinatorial peptide libraries. Eur. J. Immunol. 31(1), 156-165 (2001).
88. Tumenjargal S, Gellrich S, Linnemann T et al. Anti-tumor immune responses and tumor regression induced with mimotopes of a tumor-associated T cell epitope. Eur. J. Immunol. 33(11), 3175-3185 (2003). (Pubitemid 37428350)
89. Sharav T, Wiesmuller KH, Walden P. Mimotope vaccines for cancer immunotherapy. Vaccine 25(16), 3032-3037 (2007). (Pubitemid 46482734)
90. Van Stipdonk MJ, Badia-Martinez D, Sluijter M, Offringa R, Van Hall T, Achour A. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res. 69(19), 7784-7792 (2009).
91. Hashiguchi S, Yamaguchi Y, Takeuchi O, Akira S, Sugimura K. Immunological basis of M13 phage vaccine: regulation under MyD88 and TLR9 signaling. Biochem. Biophys. Res. Commun. 402(1), 19-22 (2010).
92. Scholl I, Wiedermann U, Forster-Waldl E et al. Phage-displayed Bet mim 1, a mimotope of the major birch pollen allergen Bet v 1, induces B cell responses to the natural antigen using bystander T cell help. Clin. Exp. Allergy 32(11), 1583-1588 (2002). (Pubitemid 35370533)
93. Monzavi-Karbassi B, Pashov A, Jousheghany F, Artaud C, Kieber-Emmons T. Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine. Int. J. Mol. Med. 17(6), 1045-1052 (2006).
94. Gameiro SR, Caballero JA, Higgins JP, Apelian D, Hodge JW. Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol. Immunother. DOI: 10.1007/s00262-011- 1020-8 (2011) (Epub ahead of print).
95. Pickford WJ, Watson AJ, Barker RN. Different forms of helper tolerance to carcinoembryonic antigen: ignorance and regulation. Clin. Cancer Res. 13(15 Pt 1), 4528-4537 (2007). (Pubitemid 47219723)
96. Mahipal A, Terai M, Berd D et al. Tumorderived interleukin-10 as a prognostic factor in stage III patients undergoing adjuvant treatment with an autologous melanoma cell vaccine. Cancer Immunol. Immunother. 60(7), 1039-1045 (2011).
97. Gross S, Geldmacher A, Sharav T, Losch F, Walden P. Immunosuppressive mechanisms in cancer: consequences for the development of therapeutic vaccines. Vaccine 27(25-26), 3398-3400 (2009).
98. Deglinnocenti E, Grioni M, Capuano G et al. Peripheral T-cell tolerance associated with prostate cancer is independent from CD4+CD25+ regulatory T cells. Cancer Res. 68(1), 292-300 (2008). (Pubitemid 351380131)
99. Sharma MD, Hou DY, Baban B et al. Reprogrammed foxp3(+) regulatory T cells provide essential help to support crosspresentation and CD8(+) T cell priming in naive mice. Immunity 33(6), 942-954 (2010).
100. Munn DH, Sharma MD, Hou D et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumordraining lymph nodes. J. Clin. Invest. 114(2), 280-290 (2004). (Pubitemid 39071633)
101. Sharma MD, Baban B, Chandler P et al. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J. Clin. Invest. 117(9), 2570-2582 (2007). (Pubitemid 47494358)
102. Perosa F, Favoino E, Vicenti C, Merchionne F, Dammacco F. Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy. J. Immunol. 179(11), 7967-7974 (2007).
103. Riemer A, Scheiner O, Jensen-Jarolim E. Allergen mimotopes. Methods 32(3), 321-327 (2004). (Pubitemid 38201286)
104. Latzka J, Gaier S, Hofstetter G et al. Specificity of mimotope-induced anti-high molecular weight-melanoma associated antigen (HMW-MAA) antibodies does not ensure biological activity. PLoS One 6(5), e19383 (2011).
105. Schijns VE, Lavelle EE. Trends in vaccine adjuvants. Expert Rev. Vaccines 10(4), 539-550 (2011).
106. Cancer and IgE. Introducing the concept of AllergoOncology. Penichet M, Jensen- Jarolim E (Eds). Humana Press, NY, USA (2010).
107. National Cancer Institute: www.cancer.gov/clinicaltrials